Results 61 to 70 of about 139,987 (302)

Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study

eJHaem
Objective We report the results of a pilot study investigating the combination of brentuximab vedotin (BV) and lenalidomide in patients with relapsed/ refractory T‐cell lymphoma. Methods A dose escalation study design was utilized.
Carrie van der Weyden, Mathias Bressel, Amit Khot, Henry Miles Prince, Michael Dickinson   +4 more
doaj   +1 more source

Autoimmune Encephalitis in Acute Care—Pathology, Diagnosis, and Management

Advanced Science, EarlyView.
ABSTRACT Autoimmune encephalitis (AE) is characterized by immune‐mediated inflammation of the brain parenchyma, presenting with various neurological syndromes, including but not limited to seizures, altered consciousness, neuropsychiatric symptoms, and movement disorders.
Suneesh Thilak, David Okoh, William Scotton, Shanika Samarasekera, Vikram Patil, Suresh Renukappa, Andrew Macduff, Subashini Suresh, Rajeev Krishnadas, Tonny Veenith   +9 more
wiley   +1 more source

EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma

, 2008
Chemotherapy with alemtuzumab and the combination of cyclophosphamide, adriamycin, oncovin, and prednisone (CHOP) has become experimental trial therapy for aggressive T-cell lymphoma. Several multicenter phase 3 trials; will incorporate this scheme.
Coenen, Jules L., Rosati, Stefano, van Imhoff, Gustaaf W., Kluin-Nelemans, Hanneke C., Boers, James E.   +4 more
core   +1 more source

Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin’s lymphoma and T-cell non-Hodgkin’s lymphoma

Haematologica, 2011
We recently reported deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Functional analyses confirmed that PTPN2 acts as classical tumor suppressor repressing the proliferation of T cells, in part through ...
Maria Kleppe, Thomas Tousseyn, Eva Geissinger, Zeynep Kalender Atak, Stein Aerts, Andreas Rosenwald, Iwona Wlodarska, Jan Cools   +7 more
doaj   +1 more source

Oral Bioinspired Peroxisome‐Engineered Probiotics for Modulating Gut Microbiota Homeostasis and Alleviating Cardiac Chemotherapy Toxicity

Advanced Science, EarlyView.
This study developed an oral bioinspired peroxisome‐engineered probiotic (BPEP) by anchoring lipid‐encapsulated ruthenium nanozymes onto Escherichia coli Nissle 1917, utilizing probiotics to deliver nanozymes to the intestinal barrier for reactive oxygen species/reactive nitrogen species elimination, tight junction restoration, and gut microbiota ...
Shuyu Wang, Xiaowan Fan, Chao Zhang, Shuai Han, Yike Guo, Yuchen Wang, Wei Wang, Junyue Xing, Ying Liu, Wei Jiang, Xiaoying Chen   +10 more
wiley   +1 more source

Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma

, 2012
Background: Hodkin s lymphoma is one of the most frequent lymphoma in western world. Despite an overall good prognosis some patients suffer relapsing tumors which are difficult to cure.
Renné Christoph, Benz Alexander H, Hansmann Martin L, Christoph, Renné, Benz, Alexander, Hansmann, Martin-Leo   +5 more
core   +1 more source

Malignant lymphomas (ML) and HIV/AIDS Infection in Tanzania. [PDF]

, 2008
\ud HIV infection is reported to be associated with some malignant lymphomas (ML) so called AIDS-related lymphomas (ARL), with an aggressive behavior and poor prognosis.
Mwakigonja Amos R, Mgaya, Edward M, Mwakigonja, Amos R, Kaaya Ephata E, Mgaya Edward M, Kaaya, Ephata E   +5 more
core   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

Advanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun, Qihong Li, Bixi Wang, Gang Wang, Ying Xue, Yibing Liang, Chenhe Hu, Zhenyu Wang, Xiaoge Gao, Haiheng Xu, Jun Song, Hailong Li, Liantao Li, Xiaoxiao Liu, Patrick Ming‐Kuen Tang, Qing Zhang   +15 more
wiley   +1 more source

The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project

, 2009
BACKGROUND: The International Peripheral T-cell Lymphoma Project was organized to better understand the T-cell and natural killer (NK) cell lymphomas, and our task is to present the clinicopathologic correlations and therapeutic results for adult T-cell
Ullrich F, Bast M, Schmitz N, Armitage J, Chhanabhai M, Reimer P, Adam P, Wilson W, Montserrat E, Au W, Kim WS, PILERI, STEFANO, Gascoyne RD, Tanimoto M, Gascoyne R, Liang R, Levine A, Rüdiger T, Holte H, Ohshima K, Berger F, Federico M, Sng I, Connors J, MacLennan KA, Uike N, Coiffier B, ZINZANI, PIER LUIGI, Bellei M, Karube K, Morishima Y, Nakamura S, Seto M, Yoshino T, Cuadros M, Weisenburger D, Müller Hermelink K, Hochberg E, Vose J, Matsuno Y, Miller T, Tamura K, Ko Y.H. ], for the International Peripheral T. Cell Lymphoma Project [Savage K, Rimsza L, Delabie J, Rajan S, Suzumiya J, Nathwani B, Alvarez Ferreira J, Loong F, Lopez Guillermo A, Armitage JO, Vose JM, Wilhelm M, Tanin I, Harris N, Weisenburger DD, Nerl C, Campo E, Anderson J, Martinez Delgado B, Jaffe E, Wannakrairot P, Tobinai K   +64 more
core   +1 more source

Peripheral T-cell lymphoma, not otherwise specified

Journal of Family Medicine and Primary Care, 2017
The peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) belongs to a heterogeneous class of aggressive neoplasms. Although several morphologic subtypes of this tumor have been described, no particular genetic, immunological, or distinct ...
Kunal Kishor Jha, Suresh K Gupta, Harpreet Saluja, Nuwadatta Subedi   +3 more
doaj   +1 more source